SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Metrics to compare | ICU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICUPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −3.8x | −0.5x | |
PEG Ratio | −0.01 | −0.28 | 0.00 | |
Price/Book | 29.2x | 2.5x | 2.6x | |
Price / LTM Sales | 38.6x | 3.7x | 3.3x | |
Upside (Analyst Target) | - | 17.2% | 43.5% | |
Fair Value Upside | Unlock | 5.1% | 6.3% | Unlock |